BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND CUX1, ENSG00000160967, P39880, p75, p200, p110, p100, Nbla10317, CUX, COY1, CDP, CASP, 1523 AND Prognosis
15 results:

  • 1. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
    Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
    Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Alternative Splicing: A New Therapeutic Target for Ovarian cancer.
    Yao S; Yuan C; Shi Y; Qi Y; Sridha R; Dai M; Cai H
    Technol Cancer Res Treat; 2022; 21():15330338211067911. PubMed ID: 35343831
    [No Abstract]    [Full Text] [Related]  

  • 3. N6-Methyladenosine-Related RNA Signature Predicting the prognosis of Ovarian cancer.
    Jiao J; Jiang L; Luo Y
    Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Pan-cancer analysis of the casp gene family in relation to survival, tumor-infiltrating immune cells and therapeutic targets.
    Hong W; Gu Y; Guan R; Xie D; Zhou H; Yu M
    Genomics; 2020 Nov; 112(6):4304-4315. PubMed ID: 32682809
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.
    Park GB; Chung YH; Kim D
    Oncol Rep; 2017 May; 37(5):3137-3145. PubMed ID: 28350104
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. cux1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms.
    Krug S; Kühnemuth B; Griesmann H; Neesse A; Mühlberg L; Boch M; Kortenhaus J; Fendrich V; Wiese D; Sipos B; Friemel J; Gress TM; Michl P
    Endocr Relat Cancer; 2014; 21(6):879-90. PubMed ID: 25248790
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. [Surgical treatment of pancreatic adenocarcinoma using cephalic duodenopancreatectomy (Part 2). Long term follow up after 204 cases].
    Fabregat J; Busquets J; Peláez N; Jorba R; García-Borobia F; Masuet C; Valls C; Ruiz-Osuna S; Serrano T; Galán M; Cambray M; Laquente B; Ramos E; Rafecas A
    Cir Esp; 2010 Dec; 88(6):374-82. PubMed ID: 21030012
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
    Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
    Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Pancreatic cancer: progress made.
    Simianu VV; Zyromski NJ; Nakeeb A; Lillemoe KD
    Acta Oncol; 2010 May; 49(4):407-17. PubMed ID: 20059311
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. [Usefulness of galectin-3 expression in the clinical behavior of differentiated thyroid carcinoma].
    López Mondéjar P; Picó A; Seguí J; López Maciá A
    Med Clin (Barc); 2008 Feb; 130(5):161-4. PubMed ID: 18341829
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Carcinoma of the body of pancreas in evolution: an aggressive disease affecting younger patients?
    Dickinson KJ; Gomez D; Lowe A; Gokhale JA; Ausobsky JR; Guillou PJ; Rahman SH
    JOP; 2007 May; 8(3):312-9. PubMed ID: 17495360
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Expression of nerve growth factor receptors and their prognostic value in human pancreatic cancer.
    Zhang Y; Dang C; Ma Q; Shimahara Y
    Oncol Rep; 2005 Jul; 14(1):161-71. PubMed ID: 15944784
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Serum tumor necrosis factor alpha receptors p55/p75 ratio and ovarian cancer detection.
    Rzymski P; Opala T; Wilczak M; Woźniak J; Sajdak S
    Int J Gynaecol Obstet; 2005 Mar; 88(3):292-8. PubMed ID: 15733884
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells.
    Zhu Z; Kleeff J; Kayed H; Wang L; Korc M; Büchler MW; Friess H
    Mol Carcinog; 2002 Nov; 35(3):138-47. PubMed ID: 12410565
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.